معرفی
Steven S. Gross is Professor of Pharmacology at Weill Cornell Medicine and a key faculty member in the Graduate School of Medical Sciences. He leads a research laboratory focused on nitric oxide (NO) signaling and directs the Mass Spectrometry Core Facility, underscoring his dual role in research and institutional infrastructure. His work bridges pharmacology, biochemistry, and cellular signaling, with significant contributions to understanding NO in vascular regulation and disease.
Dr. Gross earned his Ph.D. in Biomedical Science from Mount Sinai School of Medicine. His research interests include nitric oxide signaling, molecular pharmacology, cellular regulation, vascular biology, and metabolic pathways. His lab investigates the synthesis and action of NO, its role in septic shock, and the development of NO-based therapeutics, leading to the founding of ArgiNOx Inc.
His recent publications reveal a strong trend in cancer metabolism, redox signaling, and gene-environment interactions, with high-impact work on vitamin C in KRAS-mutant cancers, fructose and tumor growth, and epigenetic regulation by TET1. These studies span molecular oncology, metabolomics, and bioinformatics, often involving interdisciplinary collaborations.
- Active member of NIH Study Sections
- Founder and Board Director, Nitric Oxide Society
- Author of over 90 research papers and 40 book chapters
Dr. Gross actively mentors graduate students, including Tal Nuriel, Alex Hansler, Pamela Wille, Qiuying Chen, and Yuliang Ma. His lab is central to research on NO biology and mass spectrometry applications. He has no listed scientific awards in the provided texts, but his sustained publication record and leadership roles indicate significant scientific impact.
